Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Post ban diabetes drug alternative offered

  • Comment

Diabetes drug Actos (pioglitazone) would be a “sensitive alternative” to Avandia (rosiglitazone), which was banned last year, a study has revealed.

The pair are used to control blood glucose levels in type-2 diabetes patients and both are known to increase the risk of heart failure.

After rosiglitazone was banned by European authorities, researchers at the University of East Anglia analysed 16 studies including more than 800,000 patients to compare the health risks associated with each drug.

Their study indicated that patients taking pioglitazone had fewer heart problems, while Diabetes UK concluded that it was a very effective treatment.

Those taking rosiglitazone, which is still available in the US and Canada, were 16% more likely to have a heart attack, 23% more likely to suffer from heart failure and 14% more likely to die compared with those patients who were prescribed pioglitazone.

The report said: “For patients who need thiazolidinedione treatment, continued use of rosiglitazone may lead to excess heart attacks, heart failure and mortality, compared with pioglitazone, the effect on public health may be considerable.”

Have you signed our petition to ensure nurses have a seat on consortia boards? Follow @Aseatontheboard on twitter follow for all the latest campaign news!

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.